Metformin: Anchor in the Metabolic Journey of Prediabetes Care- Dr Dwaipayan Deb Written By Dr Dwaipayan Deb29 April 2026 11:24 AM ISTPrediabetes affects 634.8 million adults globally, i.e., approximately 12% of the adult population (IDF, 2025), with 30.4% prevalence among Indian...
Metformin in Weight Loss Maintenance: A Possible Opportunity Post-GLP-RA Discontinuation?- Dr. Ashok Kumar Das Written By Dr. Ashok Kumar Das21 April 2026 12:14 PM ISTPatients who achieved weight loss with GLP-1 Receptor Agonists (RAs) can sustain their results with generic anti-obesity medications, including...
Dapagliflozin and Sitagliptin FDC in Indian T2D: 5 Points Clinicians May Like to Know - Dr K Baraneedharan Written By Dr. K. Baraneedharan9 April 2026 12:00 PM ISTThe burden of T2DM is increasing worldwide, with enormous implications for morbidity and mortality. Early and effective intervention is essential to...
Metformin: Anchoring Potential in GLP-1 RA Care Journey Written By Dr Manjunath Havalappa Dodamani8 April 2026 12:59 PM ISTIndia is confronting a metabolic health crisis of significant magnitude, 254 million adults with generalised obesity, 351 million with abdominal...
Integrating Dapagliflozin and Sitagliptin FDC for Optimizing Outcomes in Type-2 Diabetes with Cardiometabolic-Based Chronic Disease (CMBCD) patients - Dr Kaushik Biswas Written By Dr. Kaushik Biswas28 March 2026 10:27 AM ISTIntroduction India's T2D population carries a substantial burden-nearly two-thirds of individuals with T2D are overweight or obese, indicating a...
T2D, Obesity and Heart Failure: Breaking the Pathophysiologic Triangle Written By Dr. Kamal Kant Kohli19 March 2026 10:15 AM ISTIndia's diabetes burden has risen markedly, with 101 million individuals living with diabetes. The clinical burden is compounded by heart failure...
T2D and CKD Risk: Can Weight Loss Alter Kidney Outcomes? Written By Dr. Kamal Kant Kohli16 March 2026 11:03 AM ISTType 2 diabetes mellitus (T2DM) represents a mounting global health crisis. India, home to 17.78% of the world's population, ranks second globally...
The Adiposity-Inflammation Axis in T2D: Implications for Heart and Kidney Written By Dr. Kamal Kant Kohli13 March 2026 10:57 AM ISTIndia is home to nearly 90 million people with T2DM , with an estimated 39.4 million remaining undiagnosed. Recent estimates from India indicate...
MASLD in T2D: Why Weight Loss Is More Than Cosmetic? Written By Dr. Kamal Kant Kohli10 March 2026 10:26 AM ISTIndia's diabetes burden is escalating rapidly, with 101 million adults currently living with T2DM (ICMR-INDIAB Study)1. Compounding this crisis,...
Beyond Glycaemia- Weight Reduction Is the New Additional Therapeutic Endpoint in T2D Written By Dr. Kamal Kant Kohli7 March 2026 10:59 AM ISTIndia bears a disproportionate share of the global diabetes burden, with 89.8 million adults living with T2DM against a worldwide estimate of 589...
Therapeutic Application of Empagliflozin, Sitagliptin, and Metformin for Advancing Overall Wellness in T2D: Evidence Review for Practitioners in 2025 Written By Dr. Manoj Chadha19 Feb 2026 10:35 AM ISTHyperglycemia in T2D plays a pivotal role in diabetic microvascular complications; however, reducing HbA1c offers only modest benefit in mitigating...
Redefining Diabetes Management With Dapagliflozin and Sitagliptin FDC: An Early, Effective and Sustainable Option For T2D Management With Risk Factors Written By Dr. Vaishali Deskhmukh12 Feb 2026 12:40 PM ISTType 2 diabetes in Indians follows a distinct and more aggressive trajectory, marked by higher insulin resistance, early Beta-cell dysfunction, lower...
